Skip to main content

Compare Stocks

Date Range: 

 Viridian TherapeuticsSirona BiochemInhibikase TherapeuticsProMIS NeurosciencesOKYO Pharma
Price Information
Current Price$17.52C$0.30$4.90C$0.19GBX 6.20
52 Week RangeBuyN/ABuyN/AN/A
Overall Score1.
Analysis Score3.
Community Score5.
Dividend Score0.
Ownership Score0.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationBuyN/ABuyN/AN/A
Consensus Price Target$34.00N/AN/AN/AN/A
% Upside from Price Target94.06% upsideN/AN/AN/AN/A
Trade Information
Market Cap$68.47 millionC$58.80 million$49.29 millionC$56.60 million£42.05 million
Average Volume50,194120,92281,068385,463361,036
Sales & Book Value
Annual RevenueN/AC$123,870.00N/AC$1,787.00N/A
Price / SalesN/A551.37N/A31,673.61N/A
CashflowN/AC$0.00 per shareN/AC$0.00 per shareGBX 0.82 per share
Price / CashN/A75.00N/A43.757.59
Book ValueN/AC$0.00 per shareN/AC$0.00 per shareGBX 0.80 per share
Price / BookN/A-150.00N/A-46.25N/A
Net IncomeN/AN/AN/AN/AN/A
EPSN/AC($0.01)N/AC($0.02)GBX (0.10)
Trailing P/E Ratio0.00N/A0.00N/AN/A
Forward P/E Ratio
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity RatioN/A2,620.27%N/AN/A0.41%
Current RatioN/A1.59%N/A0.52%17.94%
Quick RatioN/A1.57%N/A0.46%17.82%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Shares Outstanding3.91 million227.66 million10.06 million305.95 million672.82 million
Next Earnings Date8/4/2021 (Estimated)N/A7/1/2021 (Estimated)N/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
1/25/2021Viridian TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
1/20/2021Viridian TherapeuticsJefferies Financial GroupBoost Price Target
4/26/2021Inhibikase TherapeuticsThinkEquityInitiated Coverage
2/17/2019ProMIS NeurosciencesNoble FinancialReiterated Rating
11/29/2019OKYO PharmaShore CapitalReiterated Rating
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.